Idorsia Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd is a European biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Headquartered near Basel, Switzerland, the company specializes in small molecules with the potential to transform treatment options for patients. Idorsia has a 20-year history of drug discovery and a broad portfolio of innovative drugs in the pipeline, including QUVIVIQ (daridorexant) for insomnia, TRYVIO (aprocitentan) for hypertension, and Lucerastat for Fabry disease. The company was listed on the SIX Swiss Exchange in June 2017 and employs over 800 highly qualified specialists.

Idorsia is committed to responsible and sustainable business practices. The company prioritizes ethical business conduct and is committed to respecting human rights throughout its operations. They have put in place various programs to ensure compliance with external legal requirements and internal codes, as well as to promote diversity, equity, and inclusion in the workplace. Their sustainability efforts are reflected in their environmental impact management, which includes reducing energy consumption, emissions, and waste.

Idorsia values flexibility and work-life balance for its employees. They emphasize a collegial work environment that encourages employees to perform to the best of their abilities. The company provides employees with flexibility in handling work and personal commitments, supporting overall well-being, and enabling them to grow along with the company.

Idorsia provides a wide range of employee benefits, including internal and external development programs, financial assistance for further education, leadership training, coaching, and mentoring. They offer a variety of soft skills training programs at their headquarters, as well as professional work development training in the US. Idorsia also prioritizes employee health and well-being, offering on-site massages, medical checkups, relaxation pods, gym memberships, ergonomic consulting, and programs to support mental health and well-being.

Idorsia Pharmaceuticals Ltd is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative medicines to improve patient outcomes. They have a strong scientific core and a diverse portfolio of drugs targeting various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia prioritizes innovation and collaboration with academia, industry partners, and healthcare providers to ensure that their research translates into meaningful benefits for patients worldwide.

Idorsia promotes a culture of innovation, collaboration, and respect, driven by a passion for science and a commitment to improving patient lives. They value diversity, inclusivity, and personal growth, encouraging employees to achieve their full potential both professionally and personally. The company fosters a fast-paced, ambitious, and results-oriented environment where employees are expected to be proactive, pragmatic, and team-oriented, while prioritizing employee well-being and ethical business practices.

Idorsia emphasizes the importance of creating an inclusive workplace where all employees can reach their full potential. They believe that diversity, equity, and inclusion are essential for business success and have implemented initiatives such as a gender equal pay analysis, ongoing monitoring of gender pay equity, and a commitment to attracting and retaining top talent from all backgrounds. Idorsia does not tolerate discrimination of any kind and is committed to providing equal opportunities for all employees.